Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Raül, Ondoño"'
Autor:
Raimon Puig de la Bellacasa, José I. Borrell, Xavier Batllori, Jordi Teixidó, Oriol Vallcorba, Claudi de Rocafiguera, Raül Ondoño, Iñaki Galve, Cristina Puigjaner, Mercè Font-Bardia
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
Wheland intermediates are usually unstable compounds and only a few have been isolated at very low temperatures. During our work on tyrosine kinase inhibitors, we studied the bromination of 7 in order to obtain a dibromo substituted pyrido[2,3-d]pyri
Autor:
Iñaki, Galve, Raül, Ondoño, Claudi, de Rocafiguera, Raimon, Puig de la Bellacasa, Xavier, Batllori, Cristina, Puigjaner, Mercè, Font-Bardia, Oriol, Vallcorba, Jordi, Teixidó, José I, Borrell
Publikováno v:
Organicbiomolecular chemistry. 18(48)
Wheland intermediates are usually unstable compounds and only a few have been isolated at very low temperatures. During our work on tyrosine kinase inhibitors, we studied the bromination of 7 in order to obtain a dibromo substituted pyrido[2,3-d]pyri
Autor:
Alex Perálvarez-Marín, Ángel Lirio, Roger Estrada-Tejedor, Germana Falcone, Beatrice Cardinali, Claudia Provenzano, Manuel Pérez-Alonso, Raül Ondoño, Carlos Elvira, Elena Álvarez-Marimon, José I. Borrell
Publikováno v:
Computational and Structural Biotechnology Journal
Computational and Structural Biotechnology Journal, Vol 19, Iss, Pp 51-61 (2021)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Computational and Structural Biotechnology Journal, Vol 19, Iss, Pp 51-61 (2021)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Graphical abstract
Highlights • Drug design with rational methods, using structure-based methods. • Novel RNA binders based on pyrido[2,3-d]pyrimidin-7-(8H)-ones. • Myotonic Dystrophy type 1 small molecule drug discovery.
Myotonic Dys
Highlights • Drug design with rational methods, using structure-based methods. • Novel RNA binders based on pyrido[2,3-d]pyrimidin-7-(8H)-ones. • Myotonic Dystrophy type 1 small molecule drug discovery.
Myotonic Dys